|
Aug 1
|
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ
|
|
Aug 1
|
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
|
|
Jul 30
|
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
|
|
Jul 29
|
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
|
Jul 29
|
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 29
|
LEAD3R Launches 2025 Healthy Team Summit, Sponsored by The Future of Teamwork Podcast
|
|
Jul 28
|
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
|
|
Jul 28
|
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
|
|
Jul 28
|
The 3 Things That Matter for Vertex Pharmaceuticals Now
|
|
Jul 28
|
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q1 Earnings?
|
|
Jul 26
|
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
|
|
Jul 25
|
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
|
|
Jul 25
|
A Look At The Fair Value Of Vertex, Inc. (NASDAQ:VERX)
|
|
Jul 23
|
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
|
|
Jul 23
|
Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada
|
|
Jul 23
|
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
|
|
Jul 22
|
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis
|
|
Jul 22
|
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know
|
|
Jul 22
|
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
|
|
Jul 15
|
Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment
|